RESI JPM San Francisco 2023 Investor Panelists

December 15, 2022 ~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

RESI JPM San Francisco 2023 is fast approaching. The Life Science Nation (LSN) team has been busy putting together a program of 8 panels that provides latest insights on early-stage life science and healthcare.

We are excited to have invited a diverse lineup of panelists from different types of investment groups, including Big Pharma, corporate VCs, medtech strategics, traditional VCs, angels and family offices, to share their strategies and approaches on early-stage investment, perspectives on industry landscape, startup ecosystem and more. As a global conference, we are also delighted to have many international investors and cross-border investment groups to join and contribute to these dynamic discussions. The goal of RESI panels is to facilitate constructive conversations between investors and fundraising CEOs, and provide tactical advice on how companies can raise capital and acquire partnerships effectively. These must-see panels are great opportunities for founders and CEOs to engage with investors and kick off their fundraising journey of 2023.

Join the panelists below at RESI JPM San Francisco:

Mel Barsky Director of Business Development Centre for Aging + Brain Health Innovation (CABHI)	Lana Caron Innovation Lead Philips Ventures	Bruce Cohen Venture Partner Xeraya Capital
Matt Deschner Business Development & Licensing – Surgical Innovations Medtronic	Gini Deshpande Partner of Cathay Capital	Niels Emmerich Vice President, Global Head Search and Evaluation AbbVie
Xi Fang Managing Partner Button Capital	Jon Friedland Managing Director, Ventures Cleveland Clinic Ventures	Amit Garg Managing Partner Tau Ventures
Lana Ghanem Managing Director Hikma Ventures	Tom Gibbs Director Debiopharm Innovation Fund	Gita Gupta Partner NextStep Ventures
Duncan Huston-Paterson Senior Manager, Business Development Amgen	Kristin King Member Boston Harbor Angels	Fiona Mack VP, Head of CoLaborator Bayer
Nola Masterson Managing Director Science Futures	Andrew Meadow General Partner Health Innovation Capital	Tamir Meiri Senior Manager, Venture Investments Johnson & Johnson Innovation
Ole Mensching Co-Founder and General Partner Apollo Health Ventures	Ravi Mistry Angel Investor	John Parker Founder & Managing Director Springhood Ventures
Armin Rump Manager, Global Business Development Otsuka Pharmaceutical	Akhil Saklecha Chief Scientific Officer, Acute Care Danaher Corporation	Yoke Sin Managing Partner iGlobe Partners
Lesley Stolz Regional Vice President, Early Innovation Partnering Johnson & Johnson Innovation	Sally Wang Venture Partner Viva BioInnovator	Oscar Zhang Principal Qiming Venture Partners
Lu Zhang Managing Partner Fusion Fund	Cheryl Zimberlin Investment Director M Ventures

Crafting the Perfect Message

December 15, 2022October 26, 2023 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, VP of Product, Israel BD, LSN

You’ve registered for a partnering conference.

You’ve filled out a profile in the partnering system detailing who you are and what your company does.

You’ve researched the investors in attendance and built a list of targets to book meetings with.

You hit “Request a Meeting” and freeze.

What message will increase your chances of the investor accepting the request?

Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require major time investment, and we forget that, even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner. Furthermore, this is a process that requires a plan for following up, since, as with any outreach, it will likely take more than one message to the investors to receive a response. These messages should be clear and concise, no more than a paragraph, highlighting your company and what makes it unique.

Life Science Nation (LSN) has developed and consolidated your partnering outreach into four separate messages:

Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
Company tagline (5-6 words explaining who you are and what you do)
Elevator pitch (1-3 sentences describing the company and tech)
Technology differentiation, product innovation, or market position
Raise and milestone information
Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development? What makes your people special?
Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later.

It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.

Hot Investor Mandate: Leading VC in Europe Invests Up to $20M in Early and Growth-Stage Life Science Companies, With Early Clinical Data Validation in Place

December 15, 2022 ~ Next Phase Admin ~ Leave a comment

A leading European Venture Capital firm investing in early-and growth stage life science companies is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totaling EUR 1.0 billion, the firm has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, the firm has invested in over 50 innovative life science companies. Initial ticket size ranges between EUR 5-10 million and up to EUR 20 million over the life of the investment.

The firm invest mainly in Europe and selectively in US across five broad areas: Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology and R&D tools. Regarding therapeutics, the firm focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms, or with early clinical data. In the other fields, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product and have some early market traction in the single million digit range.

The firm typically requests a board seat and looks for a strong and experienced management team while supporting highly talented entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Venture Firm Seeks Medical Device & Diagnostics Companies, Most Interested in 510k Technologies

December 15, 2022 ~ Next Phase Admin ~ Leave a comment

A Venture Capital company based in USA has raised 3 funds to date and is currently investing out of its 3rd that closed at $20M. The firm makes primarily equity investments ranging from $250,000 to $5 million over the lifetime of the investment, with $100K-$500K as an initial investment. The firm has long term relationships with several Japanese medical technology corporations and also looks for ventures that they can introduce into the Japanese market. The firm prefers to invest in companies located in the West coast of the US, although they are also open to review opportunities in North America.

The firm is looking for seed and early-stage medical device and diagnostic companies. In these areas, the firm is most interested in single use therapeutic devices. The preferred regulatory pathway is a 510(k) submission, but PMA applications are also considered. Sectors with the most interest would be interventional cardiovascular and neurovascular devices, less invasive surgical instrumentation, and point of care diagnostics. The firm remains open-minded to other types of devices and indications as well.

The firm looks for professionalism in a venture’s management team and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat in portfolio companies, however they look to add value by developing corporate partnerships in Japan at the appropriate time.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: PE/VC Firm in Asia Invests $5-15M in All Life Science & Healthcare Sectors and Open to Global Opportunities

December 15, 2022 ~ Next Phase Admin ~ Leave a comment

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC. The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Actively Seeking Innovative Medical Devices in Cardiovascular and Neurovascular Diseases, Focusing on USA, Europe, Israel

December 15, 2022 ~ Next Phase Admin ~ Leave a comment

A venture capital investment firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €4-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Check Out the IPC Finalists Who Will Be Pitching at RESI JPM San Francisco 2023!

December 8, 2022December 8, 2022 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With about a month left until RESI JPM San Francisco, LSN is very excited to announce the list of finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC) at the upcoming RESI!

This round of IPC was the most popular one to date. With the increased interest, all the IPC slots were filled well before the initial application deadline.

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition, the companies will be presenting a poster showcasing their technology in the exhibit hall.

Below are the participating companies – if you will be attending RESI, please be on the lookout for them. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 1,000 attendees expected to attend, you can register here!

RESI JPM San Francisco
Innovator’s Pitch Challenge Finalists